December 4, 2015 Lake Down Room Hilton Orlando Working Breakfast 7:30 8:30 – Opening Remarks 7:45 8:00 Fred Dini – JMML Board of Directors and Patient Advocates Session #1: Update on Human Genetics 8:00 9:15 AM Organized by Elliot Stieglitz, M.D. – 8:00 8:15 Elliot Stieglitz, University of CA, SF – Alterations are Predictive of Outcome in Juvenile Myelomonocytic “Somatic Leukemia” 8:15 8:30 Hélène Cavé, Université Paris Diderot – in Juvenile Myelomonocytic Leukemia (JMML) Concomitantly Target “Mutations Several Components of the RAS-Pathway Together with the PRC2 Network” 8:30 - 8:45 Julia Obenauer, Erasmus Medical Center, the Netherlands or not: new entities and recurrent genes in JMML” “RASopathy 8:45 9:00 Hideki Muramatsu, Nagoya University – DNA methylation is associated with a poor outcome in juvenile “Aberrant myelomonocytic leukemia” 9:00 9:15 Open Discussion – Session #2: JMML and RALD 9:15 10:30 AM Organized by Katherine M.D., Ph.D. – 9:15 9:35 Masatoshi Takagi, Tokyo Medical & Dental University – history of RALD or JMML with autoimmunity who did not received HSCT” “Natural 9:35 - 9:55 V. Koneti Rao, NIAID, National Institutes of Health Spectrum of RAS-Associated Autoimmune Leukoproliferative Disorder “Clinical (RALD)” 9:55 10:15 Katherine Calvo, National Institutes of Health – and Immunophenotypic Characteristics of Ras-Associated Autoimmune “Mutational Leukoproliferative Disorder (RALD)” 10:15 10:30 Open Discussion – Break 10:30 10:45 –
December 4, 2015 Lake Down Room Hilton Orlando Working Breakfast 7:30 – 8:30 Opening Remarks 7:45 – 8:00 Fred Dini JMML Board of Directors and Patient Advocates Session #1: Update on Human Genetics 8:00 – 9:15 AM Organized by Elliot Stieglitz, M.D. 8:00 – 8:15 Elliot Stieglitz, University of CA, SF “Somatic Alterations are Predictive of Outcome in Juvenile Myelomonocytic Leukemia” 8:15 – 8:30 Hélène Cavé, Université Paris Diderot “Mutations in Juvenile Myelomonocytic Leukemia (JMML) Concomitantly Target Several Components of the RAS-Pathway Together with the PRC2 Network” 8:30 - 8:45 Julia Obenauer, Erasmus Medical Center, the Netherlands “RASopathy or not: new entities and recurrent genes in JMML” 8:45 – 9:00 Hideki Muramatsu, Nagoya University “Aberrant DNA methylation is associated with a poor outcome in juvenile myelomonocytic leukemia” 9:00 – 9:15 Open Discussion Session #2: JMML and RALD 9:15 – 10:30 AM Organized by Katherine M.D., Ph.D. 9:15 – 9:35 Masatoshi Takagi, Tokyo Medical & Dental University “Natural history of RALD or JMML with autoimmunity who did not received HSCT” 9:35 - 9:55 V. Koneti Rao, NIAID, National Institutes of Health “Clinical Spectrum of RAS-Associated Autoimmune Leukoproliferative Disorder (RALD)” 9:55 – 10:15 Katherine Calvo, National Institutes of Health “Mutational and Immunophenotypic Characteristics of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD)” 10:15 – 10:30 Open Discussion Break 10:30 – 10:45
JMML%20Working%20Group%20FINAL%20agenda.docx